A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.

Trial Details

NCT ID
NCT07568236
Phase
PHASE2
Sponsor
Chinese University of Hong Kong
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Fezolinetant
  • Placebo
Locations (sample)
  • Shatin, Hong Kong|22.38333,114.18333

Key Eligibility Criteria

  • Patients aged at least 18 years old on the index date
  • Histologically confirmed prostatic adenocarcinoma with localised or metastatic disease
  • Karnofsky index score of 70% or more
  • Started on androgen deprivation therapy (both medical or surgical), for at least 3 months at baseline

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →